Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 5/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7290720 | 0.87 | MMP2 (0.58) | MMP2MMP9ADAMTS4L3MBTL1ALDH1A1 | |
| SCHEMBL5230320 | 0.81 | CA2 (0.55) | CA2TDP1MMP2MMP9ADAMTS4 | |
| SCHEMBL8713394 | 0.77 | CA2 (0.51) | CA2TDP1ITGB3ITGA2BMMP2 | |
| SCHEMBL8713387 | 0.77 | CA2 (0.51) | CA2TDP1ITGB3ITGA2BMMP2 | |
| SCHEMBL8713009 | 0.77 | ITGB3 (0.67) | CA2TDP1ITGB3ITGA2BMMP2 | |
| SCHEMBL8713012 | 0.77 | ITGB3 (0.67) | CA2TDP1ITGB3ITGA2BMMP2 | |
| SCHEMBL1093903 | 0.77 | CA2 (0.52) | CA2ITGB3ITGA2BL3MBTL1MME | |
| SCHEMBL1093901 | 0.77 | CA2 (0.52) | CA2ITGB3ITGA2BL3MBTL1MME | |
| SCHEMBL30404207 | 0.77 | CA2 (0.52) | CA2ITGB3ITGA2BL3MBTL1MME | |
| SCHEMBL7087164 | 0.76 | ITGB3 (0.65) | CA2ITGB3ITGA2BMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622867-B1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-19 | — | — | EP | disclosed |
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL, S.A. (ES) | 2007-08-02 | — | — | US | disclosed |
| EP-1622867-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099126-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS | ALMIRALL PRODESFARMA SA (ES) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179183-A1 | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ITGA4, ITGB4, ITGA2 | CA2 2789/4885TDP1 4812/4885ITGB3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.